CytoDyn, Inc. (CYDY)
0.2654
0.00 (0.00%)
USD |
OTCM |
Jan 15, 12:40
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 337.21M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 76.66% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -0.2277 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 98.76% |
Profile
| CytoDyn, Inc. is a clinical-stage biotechnology company, which focuses on the clinical development of innovative treatments for multiple therapeutic indications based on its product candidate, leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5. Its pipeline includes Leronlimab Clinical Development Pipeline and Long-Acting CCR5 Inhibitor Development Pipeline. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA. |
| URL | http://www.cytodyn.com |
| Investor Relations URL | N/A |
| HQ State/Province | Washington |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Apr. 14, 2026 (est.) |
| Last Earnings Release | Jan. 09, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| CytoDyn, Inc. is a clinical-stage biotechnology company, which focuses on the clinical development of innovative treatments for multiple therapeutic indications based on its product candidate, leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5. Its pipeline includes Leronlimab Clinical Development Pipeline and Long-Acting CCR5 Inhibitor Development Pipeline. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA. |
| URL | http://www.cytodyn.com |
| Investor Relations URL | N/A |
| HQ State/Province | Washington |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Apr. 14, 2026 (est.) |
| Last Earnings Release | Jan. 09, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |